Ticker >

Zim Laboratories share price

Zim Laboratories Ltd.

NSE: ZIMLAB BSE: 541400 SECTOR: Pharmaceuticals & Drugs  17k   22   4

112.64
-0.66 (-0.58%)
NSE: 18 Sep 04:08 PM

Price Summary

Today's High

₹ 114.08

Today's Low

₹ 112.3

52 Week High

₹ 131.4

52 Week Low

₹ 89.5

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

548.85 Cr.

Enterprise Value

654.31 Cr.

No. of Shares

4.87 Cr.

P/E

31.09

P/B

2.36

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  47.76

CASH

0.75 Cr.

DEBT

106.21 Cr.

Promoter Holding

33.26 %

EPS (TTM)

₹  3.62

Sales Growth

-7.83%

ROE

7.86 %

ROCE

10.13%

Profit Growth

-33 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-7.83%
3 Year6.37%
5 Year1.96%

Profit Growth

1 Year-33%
3 Year43.96%
5 Year0.91%

ROE%

1 Year7.86%
3 Year9.85%
5 Year6.87%

ROCE %

1 Year10.13%
3 Year13.21%
5 Year10.5%

Debt/Equity

0.4579

Price to Cash Flow

47.84

Interest Cover Ratio

4.3273

CFO/PAT (5 Yr. Avg.)

2.36452081713847

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 33.26 0
Mar 2024 33.26 0
Dec 2023 33.26 0
Sep 2023 33.26 0
Jun 2023 33.26 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 31.6916 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.36452081713847.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.64275374339257.

 Limitations

  • The company has shown a poor revenue growth of 6.37436235269417% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
Net Sales 67.01 85.26 95.82 117.39 82
Total Expenditure 62.47 76.3 84.64 101.96 74.13
Operating Profit 4.54 8.96 11.18 15.42 7.88
Other Income 0.63 1.42 1.11 1.53 0.98
Interest 1.73 1.22 1.7 2.28 2.86
Depreciation 3.66 3.72 3.58 3.88 4.92
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.22 5.45 7.01 10.8 1.08
Tax -0.08 1.27 2.18 2.91 0.33
Profit After Tax -0.14 4.18 4.83 7.89 0.76
Adjusted EPS (Rs) -0.03 0.86 0.99 1.62 0.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 274.32 303.63 329.49 396.53 365.47
Total Expenditure 254.54 266.82 291.56 345.34 325.37
Operating Profit 19.78 36.81 37.93 51.19 40.1
Other Income 4.66 2.45 4.51 6.43 4.69
Interest 12.65 10.89 8.31 5.58 6.92
Depreciation 13.27 14.61 14.84 16.13 14.83
Exceptional Items 0 -5.18 0 0 0
Profit Before Tax -1.49 8.58 19.3 35.92 23.04
Tax -3.23 2.96 6.28 10.91 6.28
Net Profit 1.74 5.62 13.01 25.01 16.76
Adjusted EPS (Rs.) 0.36 1.15 2.67 5.13 3.44

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 16.18 16.24 16.24 48.73 48.73
Total Reserves 135.57 140.81 153.86 145.45 183.23
Borrowings 27.42 21.83 18.92 24.62 35.6
Other N/C liabilities -4.7 -2.36 1.09 12.1 13.05
Current liabilities 143.06 141.23 146.76 110.24 161.9
Total Liabilities 317.54 317.75 336.88 341.15 442.5
Assets
Net Block 111.24 103.15 103.31 107.15 160.49
Capital WIP 4.74 4.56 5.1 17.84 23.52
Intangible WIP 4.88 5.9 6.33 8.42 16.73
Investments 8.08 8.08 8.18 8.18 8.23
Loans & Advances 10.36 11.25 11.64 20.4 15.51
Other N/C Assets 1.95 1.85 0.28 0.52 0.31
Current Assets 176.29 182.97 202.05 178.64 217.71
Total Assets 317.54 317.75 336.88 341.15 442.5
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -1.49 13.76 19.3 35.92 23.04
Adjustment 25.11 24.61 20.76 20.81 21.36
Changes in Assets & Liabilities 2.59 -5.41 7.2 -14.52 -30.36
Tax Paid -4.92 -1.06 -0.23 -6.98 -2.57
Operating Cash Flow 21.29 31.9 47.03 35.23 11.47
Investing Cash Flow -18.82 -5.7 -14.42 -35.21 -71.94
Financing Cash Flow -2.16 -25.96 -32.97 0.55 59.53
Net Cash Flow 0.31 0.23 -0.36 0.57 -0.94

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 33.26 33.26 33.26 33.26 33.26
anwar daud - - - - 27.37
hasan kamal 0.21 0.21 0.21 0.21 0.21
sabbah zulfiquar kamal 3.08 3.08 3.08 3.08 3.08
shabbar daud - - - - 0.09
tasneem anwar daud 0.06 0.06 0.06 0.06 0.06
zulfiquar murtuza kamal - - - - 2.45
anwar siraj daud 27.37 27.37 27.37 27.37 -
shabbar siraj daud 0.09 0.09 0.09 0.09 -
zulfiquar kamal 2.45 2.45 2.45 2.45 -
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 66.74 66.74 66.74 66.74 66.74
bonanza business services... - - - 2.54 2.54
dr iguer abdelmounaim 2.39 2.39 2.39 2.39 2.39
investor education and pr... - - - - 3.03
llp 1.17 1.00 0.83 0.24 0.09
mathew cyriac 20.67 17.46 16.84 14.58 14.16
zakir s vali 10.36 10.36 10.36 10.36 10.36
investor education and pr... - 2.78 3.03 3.03 -
yuga stocks and commoditi... - - - 1.22 -
bonanza business services... 2.54 2.54 2.54 - -
investor education and pr... 2.78 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

ZIM Laboratories informs about analyst meet 26 Aug 2024, 5:11PM Zim Laboratories informs about newspaper publication5 Aug 2024, 4:38PM ZIM Laboratories gets nod to invest in SIA ZIM Laboratories5 Aug 2024, 10:13AM Zim Laboratories - Quaterly Results3 Aug 2024, 6:28PM Zim Laboratories - Quaterly Results3 Aug 2024, 6:28PM ZIM Laboratories’ arm gets nod to market ‘Azithromycin for Oral Suspension’ in Portugal23 Jul 2024, 10:22AM ZIM Laboratories invests Rs 68.25 lakh in ZIMTAS2 Jul 2024, 3:42PM ZIM Laboratories informs about analyst meet 14 Jun 2024, 2:31PM ZIM Laboratories gets nod to invest Rs 40 lakh in SIA ZIM Laboratories 14 May 2024, 9:59AM ZIM Laboratories gets nod to invest Rs 2 crore in ZIMTAS 14 May 2024, 9:39AM Zim Laboratories - Quaterly Results13 May 2024, 9:29PM Zim Laboratories - Quaterly Results13 May 2024, 9:29PM Zim Laboratories informs about credit rating6 Apr 2024, 3:15PM Zim Laboratories - Quaterly Results29 Jan 2024, 4:15PM Zim Laboratories - Quaterly Results29 Jan 2024, 4:15PM Zim Laboratories - Quaterly Results29 Jan 2024, 4:15PM Zim Laboratories informs about details of loss of certificate1 Jan 2024, 5:02PM Zim Laboratories informs about closure of trading window29 Dec 2023, 5:01PM Zim Laboratories informs about loss of share certificate22 Dec 2023, 4:53PM Zim Laboratories informs about loss of share certificates5 Dec 2023, 4:34PM Zim Laboratories submits analyst meet intimation4 Dec 2023, 1:08PM ZIM Laboratories informs about investor meet 25 Nov 2023, 3:39PM Zim Laboratories informs about analyst meet 21 Nov 2023, 3:21PM Zim Laboratories informs about transcript of earnings conference call15 Nov 2023, 12:38PM Zim Laboratories - Quaterly Results1 Nov 2023, 8:02PM Zim Laboratories - Quaterly Results1 Nov 2023, 8:02PM Zim Laboratories informs about board meeting 21 Oct 2023, 3:32PM ZIM Laboratories incorporates step-down Subsidiary14 Oct 2023, 2:36PM Zim Laboratories informs about analyst meet15 Sep 2023, 5:06PM Zim Laboratories informs about analyst meet 14 Sep 2023, 2:26PM Zim Laboratories informs about analyst meet14 Sep 2023, 2:03PM Zim Laboratories informs about loss of share certificates6 Sep 2023, 5:14PM Zim Laboratories informs about transcript of earnings call21 Aug 2023, 10:32AM Zim Laboratories - Quaterly Results14 Aug 2023, 6:39PM Zim Laboratories - Quaterly Results14 Aug 2023, 6:39PM ZIM Laboratories informs about disclosure 8 Aug 2023, 2:29PM Zim Laboratories informs about loss of share certificate29 Jul 2023, 3:10PM Zim Laboratories informs about AGM10 Jul 2023, 5:18PM ZIM Laboratories to make strategic investments in Australia, MENA region30 Jun 2023, 4:13PM ZIM Laboratories informs about newspaper advertisements15 Jun 2023, 5:03PM Zim Laboratories informs about disclosure12 Jun 2023, 9:36AM Zim Laboratories informs about loss of share certificate8 Jun 2023, 3:13PM Zim Laboratories informs about details of loss of certificate6 Jun 2023, 4:45PM Zim Laboratories informs about loss of share certificate20 May 2023, 3:29PM Zim Laboratories - Quaterly Results19 May 2023, 7:09PM Zim Laboratories - Quaterly Results19 May 2023, 7:09PM Zim Laboratories informs about board meeting10 May 2023, 5:06PM Zim Laboratories informs about issuance of duplicate share certificate 28 Apr 2023, 10:43AM Zim Laboratories informs about details of loss of certificate21 Mar 2023, 4:36PM ZIM Laboratories’ arm to transfer marketing authorization of Sildenafil 50 mg orally dissolving film16 Mar 2023, 11:40AM

Zim Laboratories Stock Price Analysis and Quick Research Report. Is Zim Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Zim Laboratories and its performance over the period of time. Zim Laboratories stock price today is Rs 112.55.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Zim Laboratories cash from the operating activity was Rs 11.472 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Zim Laboratories has a Debt to Equity ratio of 0.4579 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Zim Laboratories , the EPS growth was -33.0028 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Zim Laboratories has OPM of 10.9727334316169 % which is a bad sign for profitability.
     
  • ROE: Zim Laboratories have a poor ROE of 7.864 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Zim Laboratories is Rs 112.55. One can use valuation calculators of ticker to know if Zim Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Zim Laboratories
X